• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Boston Scientific could still seek to pull Synergy stent from India

September 20, 2017 By Brad Perriello

IndiaBoston Scientific (NYSE:BSX) is reportedly still considering a market withdrawal in India for its Synergy adsorbable polymer stent, after repeated attempts to lift a government-imposed price cap were rebuffed by regulators there.

Representatives from the Marlborough, Mass.-based medical device giant met yesterday with National Pharmaceutical Pricing Authority officials to discuss pulling Synergy from India, according to LiveMint. The NPPA last week said no changes to the price caps would be considered until February 2018, a year after the caps went into effect, according to the website, which cited a ” person privy to the development.”

““The company is yet to file a withdrawal application before the NPPA but they had long discussion with the price regulator. The NPPA has asked the company to reconsider their decision of withdrawal,” another source cited as “aware of the matter” told the site.

The Indian government in May rejected the company’s request to increase the cap on Synergy, with an NPPA panel ruling that there was “no major innovation” involved in the stent to warrant the higher price.

The cap has caused other major medtech players to seek to withdraw their high-end stents from India. In April, the NPPA rejected applications from Medtronic (NYSE:MDT) and Abbott (NYSE:ABT) to pull their respective Resolute Onyx and Absorb stents (Abbott has since taken Absorb off the global market, citing lackluster sales.

Even domestic players are affected, according to LiveMint, which reported that Meril Life Sciences tabled the launch of new stents in its home country.

For its part, Boston Scientific, which has said that price caps could lead to losses of at least $7 million for the year, asked the NPPA to raise the cap on Synergy from approximately $450 (INR ₹29,600) to $1,160 (INR ₹48,877), arguing that the Indian government had ignored the “exhaustive and persuasive” data which showed Synergy’s superiority.

Before the price cap was set, Boston Scientific charged $3,000 (INR ₹195,000) for the Synergy stent in the region, making the cap an effective 85% price cut.

Filed Under: Drug-Device Combinations, Featured, Stents, Wall Street Beat Tagged With: Boston Scientific, indiannationalpharmaceuticalpricingauthority

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS